MAP2K7 and atypical chronic myeloid leukemia, BCR-ABL1 negative: This unique clinical report on an aCML patient treated with trametinib, together with the results obtained in preclinical studies, highlight the need for clinical trials to test the efficacy of MEK inhibitors in larger cohorts of RAS-mutated aCML patients (Fig. 2).